The Administrative core will be responsible for the overall management of this HIVRAD. This Core will be responsible for interacting with DAIDS Program Officer and Staff as required by the funding mechanism as a multi-project cooperative agreement between our team and the NIH. The Core will coordinate all aspects of routine program management on administrative, financial, and regulator issues. The Administrative Core will also organize and interact with external advisors, and host annual external reviews. This Core has the following four Specific Aims: 1- To coordinate the interactions a) among scientists from different institutions included in the current program and b) between our team and Scientific Advisory Board members and NIH personnel regarding efficient implementation of the proposed plans and projects. 2- To oversee budgetary matters, including review and approval of subcontractual agreements, monitoring of monthly expenses and preparation of various reports. 3- To develop an Intellectual Property plan and provide logistical support for intellectual property filings and negotiations 4- To coordinate publications and presentations of results arising from these studies.
This program involves scientists working at 4 different locations throughout the US and 2 sites in South Africa. For this program to operate efficiently and productively, a centralized Administrative oversight is essential. This will be provided by Dr. Pinter and his assistants, who will be responsible for coordinating communication between the participating scientists, NIH Program Officials, and internal and external Scientific Advisory Committees, and will facilitate other scientific, legal and logistical issues that may arise.
|Qualls, Zakiya M; Choudhary, Alok; Honnen, William et al. (2018) Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. J Virol 92:|
|Perez, Lautaro G; Martinez, David R; deCamp, Allan C et al. (2017) V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS One 12:e0180720|
|Wibmer, Constantinos Kurt; Moore, Penny L; Morris, Lynn (2015) HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS 10:135-43|
|Moore, Penny L; Williamson, Carolyn; Morris, Lynn (2015) Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol 23:204-11|
|Sheward, Daniel J; Ntale, Roman; Garrett, Nigel J et al. (2015) HIV-1 Superinfection Resembles Primary Infection. J Infect Dis 212:904-8|
|Salomon, Aidy; Krachmarov, Chavdar; Lai, Zhong et al. (2014) Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. Virology 448:363-74|
|Derdeyn, Cynthia A; Moore, Penny L; Morris, Lynn (2014) Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS 9:210-6|
|Wibmer, Constantinos Kurt; Bhiman, Jinal N; Gray, Elin S et al. (2013) Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 9:e1003738|
|Sethi, Anurag; Tian, Jianhui; Derdeyn, Cynthia A et al. (2013) A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS Comput Biol 9:e1003046|
|Murphy, Megan K; Yue, Ling; Pan, Ruimin et al. (2013) Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9:e1003173|
Showing the most recent 10 out of 15 publications